HeartSciences (HSCS) vs Regentis Biomaterials (RGNT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
HeartSciences is the larger company by market cap ($15.4 million vs $11.2 million), about 1.4 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HSCS | RGNT |
|---|---|---|
| Share price | $3.18 | $1.60 |
| Market cap | $15.40M | $11.24M |
| 1-day change | +4.61% | -5.88% |
| YTD return | -1.62% | -74.78% |
| 1-year return | -18.28% | — |
| EPS (TTM) | $-3.21 | $-2.46 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.25 | $15.50 |
| 52-week low | $1.63 | $1.23 |
| Distance from 52-week high | -39.43% | -89.68% |
| Analyst consensus | buy | none |
| Avg. price target upside | +277.36% | +525.00% |
| Average volume | 154.08K | 76.78K |
| Shares outstanding | 4.84M | 7.02M |
| Employees | 14 | — |
| Sector | Health Care | Health Care |
| Industry | Industrial Specialties | Industrial Specialties |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About HeartSciences
HSCS stock →HeartSciences Inc., a medical technology company, focuses on advancing electrocardiography (ECG) through the integration of artificial intelligence. It develops artificial intelligence-enhanced electrocardiography (AI-ECG) solutions, an algorithm to detect impaired cardiac relaxation or cardiac dysfunction; MyoVista wavECG device, a resting 12-lead ECG that provides diagnostic information related to cardiac dysfunction, as well as conventional ECG information in the same test; and MyoVista Insights, a cloud-native vendor- and device-agnostic ECG management platform.
Health Care · Industrial Specialties · 14 employees
About Regentis Biomaterials
RGNT stock →Regentis Biomaterials Ltd., a regenerative medicine company, develops and commercializes tissue repair solutions in the United States. It offers Gelrin, a platform based on hydrogel matrix of polyethylene glycol diacrylate and denatured fibrinogen for the treatment and regeneration of damaged or diseased tissue; and GelrinC, a cell-free and off-the-shelf hydrogel, which is in Phase II clinical trial for the treatment of cartilage injuries in the knee.
Health Care · Industrial Specialties
HSCS vs RGNT FAQ
Which is bigger, HeartSciences or Regentis Biomaterials?
HeartSciences (HSCS) is larger, with a market capitalization of $15.40M compared with $11.24M for Regentis Biomaterials (RGNT).
Are HeartSciences and Regentis Biomaterials in the same industry?
Yes. Both are classified in the Industrial Specialties industry within the Health Care sector.